Rentschler Biopharma and Coriolis Pharma Form Strategic Alliance to Deliver Integrated Biopharmaceutical Solutions
核心洞察
Rentschler Biopharma (搜索) and Coriolis Pharma (搜索) announced a strategic collaboration to provide seamless, end-to-end solutions from early formulation through commercial manufacturing for biopharmaceutical clients.
The partnership combines Rentschler's bioprocess development and manufacturing expertise with Coriolis's formulation research and analytical capabilities to address increasing complexity in biologics development.
Clients will benefit from unified project teams, reduced tech transfer risks, and accelerated progression from early development to clinical and commercial stages.
Rentschler Biopharma (搜索), a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma (搜索), a globally operating contract research and development organization (CRDO) specializing in formulation research and development for biopharmaceuticals, announced a strategic collaboration that will provide clients with seamless, end-to-end solutions from early formulation through to commercial manufacturing.
The partnership responds to the evolving needs of the biologics market, where increasing complexity in modalities and regulatory expectations drive demand for integrated, science-driven solutions. By combining their complementary expertise, the companies aim to accelerate products' path to market while reducing development risks and complexity.
Complementary Expertise Creates Comprehensive Solution
Coriolis Pharma (搜索) brings a unique combination of in silico and wet lab formulation and drug product development expertise, scientific depth, and advanced analytical capabilities to the collaboration. The company supports every drug development phase from R&D to GMP, with a collaborative approach and deep scientific expertise that extends from discovery to commercial manufacturing and lifecycle management.
Rentschler Biopharma (搜索) contributes extensive experience in bioprocess development and manufacturing for multiple biotherapeutics, backed by a strong track record of reliability and quality. The company provides robust support from process development through to commercial supply, focusing on technical excellence, long-term partnerships, and tailored solutions to ensure successful outcomes at every project stage.
Leadership Perspectives on Strategic Value
"This marks an important step for both our organizations and for our global clients, and their patients," said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma (搜索). "Coriolis Pharma (搜索) shares our focus on technical excellence, reliability, as well as our client-centric approach. By bringing together our individual areas of excellence, bioprocess development and manufacturing on our side, and scientific and analytical expertise in formulation development at Coriolis, we look forward to addressing complex challenges across the biopharmaceutical value chain more efficiently and faster."
Silvia Steyrer-Gruber, Chief Executive Officer of Coriolis Pharma (搜索), emphasized the strategic alignment: "At Coriolis, we believe that scientific excellence, client-focused innovation, and strong partnerships are key to advancing complex biopharmaceutical programs efficiently and reliably. With Rentschler Biopharma (搜索), we have a trusted partner whose process development and manufacturing expertise ideally complements our deep understanding of formulation development and analytical services."
Client Benefits and Market Impact
The collaboration will provide clients with a unified interface and aligned project teams, reducing tech transfer risks and enabling faster progression from early development to clinical and commercial stages. This integrated approach addresses the growing complexity of biopharmaceutical development, where traditional siloed approaches can create bottlenecks and increase development timelines.
Clients will benefit from connected, science-driven solutions that help move projects forward toward success, with both organizations bringing their respective areas of excellence to create a more efficient development pathway.
Global Reach and Timeline
The integrated service offering will be available to clients starting December 2025. Both organizations maintain operations in Germany and the United States, providing global reach and local access for clients in key biopharmaceutical markets. This geographic presence ensures that the collaboration can serve the needs of both European and North American biopharmaceutical companies seeking comprehensive development and manufacturing solutions.